160 related articles for article (PubMed ID: 9327247)
1. In vitro activities of antimicrobial agents, alone and in combinations, against Burkholderia cepacia isolated from blood.
Lu DC; Chang SC; Chen YC; Luh KT; Hsieh WC
Diagn Microbiol Infect Dis; 1997 Aug; 28(4):187-91. PubMed ID: 9327247
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.
Bonacorsi S; Fitoussi F; Lhopital S; Bingen E
Antimicrob Agents Chemother; 1999 Feb; 43(2):213-7. PubMed ID: 9925508
[TBL] [Abstract][Full Text] [Related]
3. Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis.
Manno G; Ugolotti E; Belli ML; Fenu ML; Romano L; Cruciani M
Eur J Clin Microbiol Infect Dis; 2003 Jan; 22(1):28-34. PubMed ID: 12582741
[TBL] [Abstract][Full Text] [Related]
4. Endemic burkholderia cepacia bacteraemia: clinical features and antimicrobial susceptibilities of isolates.
Yu WL; Wang DY; Lin CW; Tsou MF
Scand J Infect Dis; 1999; 31(3):293-8. PubMed ID: 10482060
[TBL] [Abstract][Full Text] [Related]
5. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia.
Aaron SD; Ferris W; Henry DA; Speert DP; Macdonald NE
Am J Respir Crit Care Med; 2000 Apr; 161(4 Pt 1):1206-12. PubMed ID: 10764313
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of patients with Burkholderia cepacia bacteremia.
Huang CH; Jang TN; Liu CY; Fung CP; Yu KW; Wong WW
J Microbiol Immunol Infect; 2001 Sep; 34(3):215-9. PubMed ID: 11605815
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial resistance and DNA-fingerprinting pattern of Burkholderia cepacia blood isolates.
Saika T; Kobayashi I; Hasegawa M; Nishida M
J Infect Chemother; 2002 Dec; 8(4):341-4. PubMed ID: 12525895
[TBL] [Abstract][Full Text] [Related]
8. Burkholderia cepacia bacteremia: a retrospective analysis of 70 episodes.
Lu DC; Chang SC; Chen YC; Luh KT; Lee CY; Hsieh WC
J Formos Med Assoc; 1997 Dec; 96(12):972-8. PubMed ID: 9444917
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of antimicrobial agents, alone and in combination, against Acinetobacter baumannii isolated from blood.
Chang SC; Chen YC; Luh KT; Hsieh WC
Diagn Microbiol Infect Dis; 1995 Nov; 23(3):105-110. PubMed ID: 8849654
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and outcomes of patients with Burkholderia cepacia bacteremia in an intensive care unit.
Liao CH; Chang HT; Lai CC; Huang YT; Hsu MS; Liu CY; Yang CJ; Hsueh PR
Diagn Microbiol Infect Dis; 2011 Jun; 70(2):260-6. PubMed ID: 21392926
[TBL] [Abstract][Full Text] [Related]
11. Post-antibiotic effect of ceftazidime, ciprofloxacin, imipenem, piperacillin and tobramycin for Pseudomonas cepacia.
Kumar A; Hay MB; Maier GA; Dyke JW
J Antimicrob Chemother; 1992 Nov; 30(5):597-602. PubMed ID: 1283606
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii.
Bae S; Kim MC; Park SJ; Kim HS; Sung H; Kim MN; Kim SH; Lee SO; Choi SH; Woo JH; Kim YS; Chong YP
Antimicrob Agents Chemother; 2016 Nov; 60(11):6774-6779. PubMed ID: 27600048
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
Zhou J; Chen Y; Tabibi S; Alba L; Garber E; Saiman L
Antimicrob Agents Chemother; 2007 Mar; 51(3):1085-8. PubMed ID: 17158942
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of aminoglycosides against clinical isolates of Acinetobacter baumannii complex and other nonfermentative Gram-negative bacilli causing healthcare-associated bloodstream infections in Taiwan.
Liu JY; Wang FD; Ho MW; Lee CH; Liu JW; Wang JT; Sheng WH; Hseuh PR; Chang SC
J Microbiol Immunol Infect; 2016 Dec; 49(6):918-923. PubMed ID: 26364729
[TBL] [Abstract][Full Text] [Related]
15. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.
Giamarellou H
Am J Med; 1986 Jun; 80(6B):126-37. PubMed ID: 3088998
[TBL] [Abstract][Full Text] [Related]
16. Major Aspects of Burkholderia gladioli and Burkholderia cepacia Infections in Children.
Bedir Demirdag T; Ozkaya Parlakay A; Aygar IS; Gulhan B; Kanik Yuksek S
Pediatr Infect Dis J; 2020 May; 39(5):374-378. PubMed ID: 32118858
[TBL] [Abstract][Full Text] [Related]
17. In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli.
Critchley IA; Sahm DF; Kelly LJ; Karlowsky JA
Chemotherapy; 2003 May; 49(1-2):44-8. PubMed ID: 12714810
[TBL] [Abstract][Full Text] [Related]
18. Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland.
Pitt TL; Kaufmann ME; Patel PS; Benge LC; Gaskin S; Livermore DM
J Med Microbiol; 1996 Mar; 44(3):203-10. PubMed ID: 8636938
[TBL] [Abstract][Full Text] [Related]
19. Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.
Papp-Wallace KM; Becka SA; Zeiser ET; Ohuchi N; Mojica MF; Gatta JA; Falleni M; Tosi D; Borghi E; Winkler ML; Wilson BM; LiPuma JJ; Nukaga M; Bonomo RA
ACS Infect Dis; 2017 Jul; 3(7):502-511. PubMed ID: 28264560
[TBL] [Abstract][Full Text] [Related]
20. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.
Livermore DM; Mushtaq S; Ge Y; Warner M
Int J Antimicrob Agents; 2009 Nov; 34(5):402-6. PubMed ID: 19428220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
